anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. A method of treating or enhancing the treatment of a disorder selected from: a) Obsessive Compulsive Disorders (OCD); and/or b) Panic Disorder (PD); comprising administering a therapeutically effective, nontoxic dose of reboxetine and derivatives and or pharmaceutically acceptable salts thereof to a patient experiencing the symptoms of those disorders. 2. The method of claim 1 where reboxetine is used to treat or enhance the treatment of Obsessive Compulsive Disorders (OCD). 3. The method of claim 1 where reboxetine is used to treat or enhance the treatment of Panic Disorder (PD). 4. The method or use in claims 1-3 where the reboxetine dose range is 4 to 10 mg. per patient per day. 5. The method or use in claims 1-3 where the reboxetine dose range is 6 to 8 mg. per patient per day. 6. The preparation of a medicament to treat OCD or PD from a composition comprising a therapeutically effective of reboxetine or its derivatives and/or pharmaceutically acceptable salts thereof as an active substance or pharmaceutically acceptable carrier. 7. The preparation of a medicament of claim 6 comprising from 4 to 10 mg per day of reboxetine. 8. The preparation of a medicament of claim 6 comprising from 6 to 8 mg per day of reboxetine. 9. The use of reboxetine or its pharmaceutically acceptable salts in the manufacture of a medicament to treat Obsessive Compulsive Disorders (OCD); and/or Panic Disorder (PD); and/or for the treatment of any of the symptoms of either of those diseases. 10. The method or use in claim 9 where the reboxetine dose range is 4 to 10 mg. per patient per day. 11. The method or use in claim 9 where the reboxetine dose range is 6 to 8 mg. per patient per day.
This screening protocol is designed to facilitate patient recruitment to the National Institute of Nursing Research (NINR) clinical research studies on pain and fatigue syndromes. This protocol will also validate the newly developed Saligan Fatigue Questionnaire. Patients must meet the specific requirements of an IRB-approved research study; this protocol serves as a first step for evaluating patients for possible inclusion in a natural history or intervention protocol.

Candidates will be screened with medical history/physical examination, routine laboratory tests, and questionnaires. The physical examination may include the standardized tender point assessment as specified in the American College of Rheumatology (ACR) to diagnose fibromyalgia, measurements of pain (allodynia, hyperalgesia, and hyperpathia), edema, autonomic dysfunction (altered skin color, temperature, or sudomotor activity), and extent of musculoskeletal dysfunction. It will also assess the patients level of pain, fatigue, and quality of life by providing questionnaires for the patients to complete. When the screening is completed, patients will be informed of their options to participate in other NINR interventional or observational clinical research studies. Patients who are not eligible for these studies will be informed of alternative treatments. No treatment is offered under this protocol. Information collected in this protocol will be used to determine eligibility to other NINR protocols.
Rationale: Previous research indicates that high dose aldesleukin produces tumor regression through upregulation of the patients' immune system. Research suggests that sorafenib directly targets tumors by inhibiting angiogenic activity with possibly some cytotoxicity. Angiogenic refers to the formation of new blood vessels that support tumor growth. Cytotoxicity is the measurement of a chemical's ability to damage or kill cancer cells. Researchers have hypothesized that the complementary ways aldesleukin and sorafenib work, and their non-overlapping toxicity profiles, may create a reasonable combination for the treatment of metastatic renal cell carcinoma and metastatic melanoma. The current Phase I study will evaluate toxicity in patients through assessing various dose levels of sorafenib in combination with aldesleukin.

Purpose: The primary objective is to determine the maximum tolerated dose and characterize the toxicity of high dose aldesleukin and sorafenib in patients with unresectable or metastatic clear cell renal carcinoma and metastatic melanoma. Secondary objectives include determining progression free survival in patients, evaluating in a preliminary manner response rates, and assessing other measurements in study participants.

Treatment: Study participants will be given bolus high dose aldesleukin and sorafenib. Aldesleukin will be provided through intravenous infusions on days 1 through 5. Each 5 day treatment is considered a cycle. The second cycle of aldesleukin will start on day 15. Two cycles are considered 1 course. All study participants will be given the same dose level of aldesleukin. No dose reductions will be permitted. Sorafenib will then be administered on day 29. Since this study will assess the maximum tolerated dose of sorafenib, some study participants will receive different amounts of this drug compared to others depending upon when each individual enrolls in the study. Each group of 3 to 6 study participants will receive a higher dose of sorafenib until the maximum tolerated dose is established. Imagining studies will be performed to determine response to treatment during week 12. If the patient has stable or responding disease, a second course will be administered on the same schedule. Patients without disease response will be given one additional course of aldesleukin past maximal response. When it is decided that no further aldesleukin will be provided to patients, sorafenib at the Food and Drug Administration approved dose may be continued until there is a lack of clinical benefit or intolerable side effects develop. Several tests and exams will be given throughout the study to closely monitor patients.
Disclosed are a thiazolone derivative of N6022 and a pharmaceutical use thereof. The characteristic structure of the thiazolone derivative of N6022 is:Compared to N6022, the compound of the present disclosure has good oral bioavailability and a longer half-life period. In in-vitro experiments, administering the compound of the present disclosure can improve migration ability, tube formation ability and, the permeability of human umbilical vein endothelial cells caused by high glucose, and administering the compound of the present disclosure at an animal level can obviously promote the angiogenesis and blood flow recovery of ischemic lateral limbs of diabetic mice. Overall, it suggests that the compound of the present disclosure can be used for treating diseases related to diabetic vascular complications. In in-vitro experiments, administering the compound of the present disclosure can improve phenotypic switch of smooth muscle cells due to angiotensin II, and administering the compound of the present disclosure at an animal level can obviously improve the incidence rate and mortality rate of aortic aneurysm/dissection. This suggests that the compound of the present disclosure can be used for treating diseases related to aortic aneurysm/dissection. In in-vitro experiments, administering the compound of the present disclosure can effectively inhibit the GSNOR activity, suggesting that the compound of the present disclosure can be used for treating diseases related to asthma and cystic fibrosis.
<P>PROBLEM TO BE SOLVED: To provide an image diagnostic apparatus capable of simply displaying data of a plurality of modalities.  <P>SOLUTION: A patient ID is input by a user, and basic data such as the name, height, and weight of the patient corresponding to the input patient ID are acquired from a patient ID table 21 in a data server 2. Next, an examination number counting part 54 counts the number of examinations descried on the patient ID in the own image diagnostic apparatus 3a. Next, a list acquisition part 52 transmits the patient ID to other image diagnostic apparatuses 3b-3e via a communication part 15, and acquires a list on the patient ID to be stored in a storage part 16. Then, the examination number counting part 54 counts the number of examination described in the acquired list for each of the other image diagnostic apparatuses. When all the counting is finished, an integrated list creating part 55 creates an integrated list describing the patient ID and the number of examinations described in the lists of the respective image diagnostic apparatuses including the own image diagnostic apparatus to be displayed in a display part 12.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A computer implemented method of creating display configurations includes generating, via a medical record dashboard system, a dashboard display comprising at least a first visible panel of one or more visible panels having selected information corresponding to information stored in one or more medical record databases related to different respective medical services. A configuration menu associated with the first panel is displayed and display configuration parameters selected by a first user for a first display configuration are received in response to user interaction with the display configuration menu. The first panel is configured based on the first configuration and the display configuration parameters of the first configuration are stored. A selection of the first display configuration by a second user may be received via a configuration sharing panel. The first display configuration is retrieved as is data defined by the first display configuration. The first display configuration is then applied to a second panel selected by the second user.
Chronic pain affects over 100 million Americans, costs the US over $630 billion annually, and reduces quality of life. It is among the most clinically challenging and financially burdensome conditions facing clinicians and healthcare organizations. Sleep disturbance is common in chronic pain conditions with some studies reporting a prevalence as high as 70%-88%. Psychiatric disorders, including substance abuse and mood disorders are prevalent in chronic pain and are associated with impairment and decreased quality of life. Sleep is increasingly recognized as a critical regulator of mental health. Taken together, epidemiological, cross-sectional, and prospective studies support the hypothesis that insomnia, chronic pain, and depression are mutually interacting, each increasing the risk for the emergence and/or exacerbation of the other. The gold standard of chronic pain management is multidisciplinary pain treatment (MPT), but patients rarely receive MPT secondary to limited access and a severe shortage of pain management specialists. Thus, there is an urgent need for empirically supported, cost-effective multidisciplinary pain self-management options that are accessible to patients and trusted by primary and tertiary care providers. To address this problem, the investigators' group in collaboration with the Johns Hopkins Technology Innovation Center (TIC) has developed a mobile chronic pain, medication and symptom tracking digital technology platform designed to eventually support multidisciplinary pain treatment by enhancing patient-provider communication and delivering comprehensive, personalized, interactive evidence-based pain management strategies. The investigators' App (version 1.3) is currently able to collect self-report data (i.e., pain; sleep; mood; catastrophizing; stress; pain flares) and continuous, passively collected wearable biosensor data (i.e., heart rate; breathing; sleep; heart rate variability/stress). The investigators propose a prospective, observational proof of concept study to demonstrate feasibility and adherence while establishing the psychometric properties of a mobile pain App and to compare these data with passively collected physiological data and laboratory indices of pain in patients with chronic low back pain (CLBP).
Male adults non-diabetic and non-dialyzed CKD stage 5 patients. All the CKD patient will be recruited at the Department of Nephrology of Edouard Herriot University Hospital (Lyon, France).
Tramadol (im.) for once \& Tramcontin (po.) for routine use during the first 3 postop. days.
Placebo twice a day using a multidose dry powder inhaler (MDPI) for 12 weeks in a double-blind manner. During the run-in and the treatment periods, all subjects replaced their current rescue medication with albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI) (90 mcg/actuation) for use on an as needed basis for the relief of asthma symptoms.
This is a multi-center, prospective, blinded clinical study designed to evaluate clinical utility of Nevisense in normal clinical practice, i.e. the potential effect of implementing Nevisense in clinical decision making (Human vs Human \& Machine) based on Nevisense measurement after biopsy decision. The study enrollment will continue until minimum of 180 subjects are enrolled in the study. Up to 3 US university/hospital investigational sites will participate in this study. Biopsying clinician or the investigators from the clinical practices of physicians participating in the study will perform the patient and lesion assessment for biopsy as standard of care at the clinic.

Study subjects will be recruited from the clinical practices of physicians participating as investigators in this study. Biopsying clinicians provide their assessment to whether s/he would have sent the lesion(s) for biopsy had s/he known the EIS information beforehand . Thereafter an evaluation of the suspicious lesion with the Nevisense will be performed followed by a biopsy of the lesion. The biopsied lesion will be subjected to histological analysis.
PROBLEM TO BE SOLVED: To provide a method and a system for managing and analyzing biomedical equipment data in a medical institution. SOLUTION: Biomedical equipment data records in a medical institution (12) are stored in a database (36) and are integrated with other information sources (60 and 122) which are located on the inside and outside of the institution. Equipment data can include identifiers of equipment components (C1, C2, etc.), department assignments, positions of facility sites, operation result data, service data, etc. Additional information resources can include a hospital information system (48), a department information system (46), financial records (122), external reference materials, and reference data (60) of an institution having a similar profile. These additional resources give criteria for more detailed analysis, planning, and reporting with respect to equipment inventories, results of operation, and service execution.
Compositions, kits, and methods for preparing nutrient compositions are provided. A nutrient composition can be a food composition such as a dairy composition. A nutrient composition may be produced by an engineered cell composition. Compositions, kits, and methods for preparing engineered cell compositions for producing nutrient compositions are also provided. An engineered cell composition may comprise genetically engineered cells, such as genetically engineered mammary or mammary-like cells. An engineered cell composition can be derived from mammalian stem cells, such as non-mammary adult stem cells. Related methods of characterization, such as for characterizing the engineered cell compositions or the nutrient compositions, are also provided.
OBJECTIVE: Neurophobia is well recognized as dissuading medical students from neurocentric specialties and limiting the success of neurology and neurosurgery teaching at medical school. Past studies have associated neurophobia with deficiencies in medical education. We performed a cross-sectional analysis of medical students' confidence and perceived level of knowledge in recognizing the following neurosurgical and neurological emergencies: ischemic stroke, hemorrhagic stroke, status epilepticus, subarachnoid hemorrhage, increased intracranial pressure, acute hydrocephalus, spinal cord injury, cauda equina syndrome, and traumatic brain injury. In addition, we assessed the usefulness of virtual seminars in neurosurgery and neurology teaching.
METHODS: Medical students from King's College London were invited to a virtual teaching session. We obtained preteaching and postteaching scores for students' subjective ability to recognize specific neurologic and neurosurgical emergencies, along with their confidence in the subject.
RESULTS: Ninety-seven medical students attended the teaching session. For our sample group's subjective rating on their confidence in neurology or neurosurgery as a subject, we obtained a mean score of 3.87 and a median score of 4. Across all domains, there was a significant forward shift in the distribution curve of scores after teaching. We obtained statistically significant differences for all 9 neurologic and neurosurgical emergencies evaluated in our questionnaire (asymptotic significance <0.001). Median scores for all 9 conditions improved after the teaching session, with >50% positive ranks seen within each group. Across the teaching modalities compared, placement teaching was the highest scoring, whereas online lectures received a better rating than in-person lectures.
CONCLUSIONS: In neurosurgery teaching, virtual seminars may compensate for deficiencies that exist within medical education, hence limiting the effects of neurophobia.
The recommended dose of Entacapone Tablets is one 200 mg tablet administered concomitantly with each levodopa and carbidopa dose to a maximum of 8 times daily (200 mg x 8 = 1,600 mg per day). Clinical experience with daily doses above 1,600 mg is limited.

Entacapone Tablets should always be administered in association with levodopa and carbidopa. Entacapone has no antiparkinsonian effect of its own.

In clinical studies, the majority of patients required a decrease in daily levodopa dose if their daily dose of levodopa had been greater than or equal to 800 mg or if patients had moderate or severe dyskinesia before beginning treatment.

To optimize an individual patient’s response, reductions in daily levodopa dose or extending the interval between doses may be necessary. In clinical studies, the average reduction in daily levodopa dose was about 25% in those patients requiring a levodopa dose reduction. (More than 58% of patients with levodopa doses above 800 mg daily required such a reduction.)

Entacapone Tablets can be combined with both the immediate and sustained-release formulations of levodopa and carbidopa.

Entacapone Tablets may be taken with or without food (see CLINICAL PHARMACOLOGY).
Incretins, the analogs of glucagon-like peptide-1 (GLP-1), improve glucose control in type 2 diabetes mellitus and counteract obesity through mechanisms that are not completely understood. The investigators' preliminary data show that, in prediabetic human subjects and mice, GLP-1 analog therapy induces an increase in plasma interleukin-6 (IL-6), a cytokine activating signal transducer and activator of transcription 3 (STAT3) signaling, which induces brown (beige) adipocyte differentiation in adipose tissue (AT). The investigators discovered that plasma IL-6 induction occurs through GLP-1 receptor (GLP-1R) stimulation in leukocytes. Interestingly, studies in rodents indicate that GLP-1 / GLP-1R signaling also induces AT beiging. Based on these observations, the investigators hypothesize that incretins induce AT browning in part via transient IL-6 / IL-6 receptor (IL-6R) / STAT3 signaling. The primary objective is to further elucidate the role of IL-6 and GLP-1 signaling in mediating beneficial metabolic effects of incretin therapy. Studies will be paralleled in a human clinical trial, a human cell culture model, and a mouse diet-induced obesity model. GLP-1 analog therapy combined with an IL-6 blocking antibody will be used. Specific Aim 1 is to (A) investigate IL-6 induction / downstream STAT3 signaling and AT browning upon incretin therapy in prediabetic human subjects; and (B) validate mice as a model to study incretin-induced IL-6 signaling as a mediator of AT browning. Specific Aim 2 is to (A) investigate if GLP-1 analog effects on beige adipogenesis depend on IL-6 signaling in human adipocyte progenitors; and (B) investigate if GLP-1 analog effects on beige adipogenesis depend on IL-6 signaling in mice. It is expected that 1) GLP-1 analog signaling via GLP-1R induces IL-6 secretion by leukocytes, and 2) GLP-1 analog therapy induces adipose tissue browning via both direct GLP-1 / GLP-1R signaling and indirect incretin-induced IL-6 / IL-6R / STAT3 signaling. The results of this novel study will give critical insights on the anti-obesity mechanisms of GLP-1 analogs and serve as the basis for developing more targeted therapies for diabetes and obesity. Understanding the anti-diabetic IL-6 effects will also be important for interpreting the results of IL-6 blockade, a therapeutic approach for patients with diabetes and other inflammatory conditions, which may need to be re-considered.
The present invention relates to a buccal tablet for treating oral anaerobe infection diseases and a preparation method thereof. The buccal tablet can effectively solve the disease treatment problem caused by anaerobe. The tablet is prepared from metronidazole, sodium carboxymethylcellulose, dextrin, stevioside, mannitol, sucrose, citric acid, menthol, peppermint oil, essence, ethanol solution and magnesium stearate. The preparation method of the buccal tablet comprises the following steps: the sucrose, the mannitol, the metronidazole, the sodium carboxymethylcellulose, the dextrin and the stevioside are respectively pulverized and sieved to be evenly mixed according to the requirement of the compounding ratio; a wetting agent prepared from the ethanol solution and the citric acid is added; granules are prepared and dried; the menthol, the peppermint oil and the essence are mixed to be prepared into volatile oil, and the volatile oil is sprayed on the dry granules according to the requirement of the compounding ratio; the magnesium stearate is added into the medicament granules, the medicament granules are pressed into tablets, and the buccal tablet is obtained. The buccal tablet has the advantages that the ingredients are scientific and reasonable, a person can easily take the buccal tablet, the therapeutic effect is good, the preparation method is advanced, and the buccal tablet is an invention on the basis of the existing antibiotic medicament. The popularization and the application of the buccal tablet provide the creativity contribution for people's good health.
There are provided bio-compatible means for delivery of at least one pharmaceutically active agent to a patient in need of same, comprising a bio-compatible, bio-degradable anionic or cationic carrier and at least one pharmaceutically active agent wherein the agent is cationic when the carrier is anionic and is anionic when the carrier is cationic. The delivery means further comprises at least one bio-compatible enclosing means for the carrier. This enclosing means may be bio-degradable or non bio-degradable and have a predetermined permeation gradient for the passage therethrough of the at least one pharmaceutically active agent. In an alternate embodiment the enclosing means may be biodegradable without a predetermined permeation gradient for the passage therethrough of the at least one pharmaceutically active agent. In all embodiments the active agent is ionically linked to the carrier and the carrier/active agent combination is enclosed in the enclosing means. There is also provided a method of administering at least one pharmaceutically active agent to the tissue surface of a subject in need of same at a rate dependent on the permeability and/or bio-degradability of the enclosing means of the delivery means which comprises contacting the tissue surface with a bio-compatible delivery means as described above.